{"title": "Find a Doctor", "author": null, "url": "https://www.dana-farber.org/find-a-doctor/f-stephen-hodi/", "hostname": "dana-farber.org", "description": "F. Stephen Hodi, MD - Medical Oncology. Dr. Hodi is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women's Cancer Center and Professor of Medicine at Harvard Medical School. He received his MD degree from Cornell University Medical College in 1992. Dr. Hodi competed his postdoctoral training in ...", "sitename": "F. Stephen Hodi, Jr., MD - Dana-Farber Cancer Institute", "date": "2018-07-18", "cleaned_text": "and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade. Cancer Immunol Res. 2023 08 03; 11(8):1100-1113. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37262321) Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials. Cancer Epidemiol Biomarkers Prev. Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2023 Jun 13; 29(12):2336. View in: phase and View in: Liver Specialist Consultation is Associated With Faster Biochemical Resolution of Severe Immune Checkpoint Inhibitor-Induced Hepatitis. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37308118) Profiling of Natural Killer Interactions With Cancer Cells Using Mass Cytometry. Lab Invest. 2023 08; 103(8):100174. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37169083) Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + 46(5):192-196. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37115942) Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 2023 04 13; 141(15):1817-1830. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36706355) Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. Cancer Cell. 2023 04 10; View J. 2023 Mar; 10(3):e01018. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36998343) Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. J Clin Oncol. 2023 Feb 10; Impact Jan-Feb 01; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36219700) inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course. Cancer. 2023 02 01; 129(3):367-375. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36377339) Chemotherapy Dose Shapes the Expression of Immune-Interacting Markers on Cancer Cells. mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. Cancer Cell. 2022 10 10; 40(10):1161-1172.e5. View in: interferon alfa-2b for resected high-risk stage III-IV in phase III trial E1609. 27. View in: Placebo-Controlled, III With Pembrolizumab for Advanced Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. Res. 2022 08 15; 28(16):3452-3463. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35699599) Mechanical checkpoint 2022 Molecular rare immune-related adverse events in a colon cancer patient with genomic cytokine profiling. Immunotherapy. 2022 08; 14(11):843-850. Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. J barcoding, and cryopreservation of Nivolumab in Advanced View in: 18; an Intratumoral STING Agonist, in Patients with Advanced/Metastatic or hypofractionated radiotherapy metastatic Ipilimumab or Nivolumab Alone Versus Ipilimumab in cells with PD-1 blockade after stem cell transplantation: an index case. 2021 11 23; 5(22):4701-4709. in: in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours first-in-human, 22(12):1740-1751. outcomes of with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of 12 15; 81(24):6131-6141. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34728538) Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and 2021 in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34406158) Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. Eur J Cancer. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34571336) strategies for intratumoural immune Eur J 16; 184(19):4996-5014.e26. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34534464) Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell Inhibition with Targeted Low-dose or Hypofractionated Radiation Patients Colorectal in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34470811) TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. dendritic cells in features of CTLA-4 blockade for myeloid malignancies Solid Cancer Res. 2021 07 15; 27(14):4025-4035. View in: adverse with adjuvant ipilimumab in use of immunosuppressants and association with Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. Clin Cancer Res. 2021 07 01; 27(13):3620-3629. of an analysis 2021 04 01; 31(2):181-185. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33625104) Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. Cancer Med. 2021 04; 10(8):2627-2635. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33724703) Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation nivolumab plus ipilimumab with BRAF plus MEK inhibitors for 2021 04; efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). Melanoma Res. 2021 02 01; 31(1):67-75. View in: A molecular response of marginal zone to front-line adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Res. for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clin Cancer Res. 2021 safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. Eur J Cancer. 2021 02; 144:182-191. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33360855) A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021 07; 100(1):196-205. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33359528) Conserved Interferon-? Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2021 Jan 11; 39(1):122. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33306984) Correction: From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2020 Dec; 20(12):757. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33046838) Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33759777) Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain 15; 126(24):5274-5282. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32926760) Conserved Interferon-? Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2020 10 12; 38(4):500-515.e3. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32916126) Fitness Landscape of Clonal Hematopoiesis Pressure of Immune Checkpoint Blockade. JCO Precis Oncol. 2020; 4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33015529) Outcomes of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Cancer. 2020 Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 Aug; 26(8):1307. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32587393) Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clin Cancer Res. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32605909) Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell. 2020 08 06; 182(3):655-671.e22. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32603654) Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer. 2020 08 15; 126(16):3758-3767. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32552274) Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight. 2020 06 18; 5(12). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32484797) Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. JCO Oncol Pract. single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 05; 26(5):792-802. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32405060) Inactivation of Fbxw7 Impairs 09; 10(9):1296-1311. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32371478) Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunol Res. 2020 08; 8(8):1075-1084. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32321774) Standardized 11-color flow cytometry panel for the functional phenotyping of human T regulatory cells. J Biol Methods. Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. 06 01; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32019858) Phase III Study of Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for High-Risk Melanoma: on in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker 2019 Apr; 30(4):589-596. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31987276) Five-year survival outcomes patients advanced melanoma with pembrolizumab in KEYNOTE-001. exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019 Nov; 20(11):1556. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31582823) Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. Ipilimumab in Melanoma. N Engl 381(16):1535-1546. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31562797) Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. J Clin 2019 Aug; 25(8):1319. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31267021) Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clin Cancer Res. 2019 10 15; 2019 06; 25(6):929-935. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31171876) Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry. J Biol Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. Am Soc Clin Oncol Educ Book. 2019 High-Dose Glucocorticoids the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Res. 2019 07; 7(7):1214-1220. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31088848) Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J Immunother Cancer. 2019 04 24; 7(1):112. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31014385) The Intersection between Tumor Angiogenesis and Immune Suppression. Clin Cancer Res. 2019 09 15; 25(18):5449-5457. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30944124) Five-year survival outcomes for patients advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann on in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. Ann 2019 04 01; 30(4):589-596. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30689736) Complex inter-relationship body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019 03; 20(3):326-336. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30778252) 25(11):3220-3228. View in: Toxicity of 2019 02 01; 40(1):17-65. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30184160) irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res. 2019 04 01; 25(7):2174-2184. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30670497) Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma. Cancer Immunol Res. 2019 03; 7(3):458-465. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30635271) Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018 Dec 01; 24(23):6098. View in: from of Cancer Immunotherapy: Current Future Directions. Radiology. 2019 01; 290(1):9-22. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30457485) A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30388455) Separation, banking, and quality control of peripheral blood mononuclear cells from whole blood of melanoma patients. Cell Tissue Bank. 2018 Dec; 19(4):783-790. View Nivolumab plus 067): 4-year outcomes of Oncol. 2018 11; 19(11):1480-1492. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30361170) Characterization Pancreas. 2018 10; 47(9):1123-1129. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30153220) The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. Int J melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer. 2018 09; 119(6):670-674. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30202085) Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunol Immunother. 2018 Dec; 67(12):1833-1844. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30191256) Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; Metastatic to Brain. N 379(8):722-730. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30134131) Cell. 2018 08 09; 174(4):1031-1032. View in: follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Eur J Cancer. 2018 09; 101:114-122. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30053670) MHC proteins confer differential and PD-1 blockade in untreated metastatic melanoma. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunol Res. 2018 09; 6(9):1039-1045. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30002157) An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. Cancer. 2018 05 30; 6(1):44. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29848375) Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018 View Cancer-Germline Antigen Expression Discriminates 04 19; 173(3):624-633.e8. View in: Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event. Cancer Immunol Res. 2018 06; 6(6):630-635. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29622582) Efficacy in older a meta-analysis. Cancer. 2018 04 04; 6(1):26. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29618381) Isolation and characterization of circulating cells by size filtration and fluorescent Anti-CTLA-4 based anti-CTLA-4 and anti-PD-1 immunotherapy View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29510697) Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. 2018 04 15; 24(8):1805-1815. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29358500) Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018 Feb 16; 359(6377):801-806. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29301960) Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer. 2018 03 15; 124(6):1111-1121. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29313945) Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018 01; 19(1):e20-e32. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29304358) Durable Complete Response After Discontinuation Pembrolizumab in Metastatic of Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma. Genes Dis. 2018 Mar; 5(1):46-48. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29619406) 2018 View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29101162) Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. J Immunother. 2017 Nov/Dec; 40(9):334-340. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29028788) comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical JAMA Oncol. 2017 Nov 01; 3(11):1511-1519. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28662232) Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. Cancer Immunol Nov 02; View Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced 2017 Dec Nivolumab Ipilimumab in Melanoma. N 2017 Sep 07; 170(6):1109-1119.e10. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28886381) Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin Oncol. 2017 after progression on previous PD-1/PD-L1 inhibitors: J Immunother Cancer. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28815046) Response after progression on previous PD-1/PD-L1 inhibitors: Immunother inhibitor locally advanced or metastatic melanoma [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28729151) Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. Clin Cancer 01; 23(19):5737-5744. life results from the phase III CheckMate 067 study. Eur J Cancer. 2017 09; 82:80-91. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28651159) Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. Clin Cancer Res. 2017 Aug 15; 23(16):4671-4679. in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Ann Oncol. 2017 Jun 01; 28(6):1380-1387. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28327988) Development of antibody panel for functional phenotyping of human CD8+ cytotoxic T cells from peripheral 70(1):1-11. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28551826) Oncol. 2017; 1. View a Biomarker in Malignant Melanoma with Checkpoint 2017 06; 5(6):480-492. View in: Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes. Cancer 2017 06; combined BRAF/MEK inhibition after advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer. 2017 Sep 01; 123(17):3285-3290. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28440953) Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. Cancer Immunol Res. Colonoscopy for Immune-Related Colitis in in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28373217) iRECIST: guidelines for response in immunotherapeutics. Lancet Oncol. 2017 Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Cancer 04; 5(4):312-318. View in: View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28239469) Adoptive NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. Clin Res. 2017 Jul 15; 23(14):3510-3519. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28193627) Evaluation Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative with a worse prognosis in metastatic the Era of Precision Medicine: Radiologists Should Know. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28096717) Angiopoietin-2 as Immune Immunol Res. 2017 01; therapy in non-small-cell lung cancer patients. J Immunother Cancer. 2016; 4:84. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28018599) Gene 97(2):207-216. View of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review Distinct View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27856426) Safety Profile of Nivolumab Monotherapy: A Pooled Analysis With Haematol. 2018 03; 180(5):752-755. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27861725) Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled View in: 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in of Anti-TYRP1 IMC-20D7S for Patients with Relapsed or Refractory Cancer Res. 2016 Nov 01; 22(21):5204-5210. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27797971) Results from an Integrated of Urelumab, an Agonist Anti-CD137 Monoclonal [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27756788) A phase of panobinostat (LBH589) in patients with metastatic melanoma. Cancer Med. 2016 11; 5(11):3041-3050. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27748045) Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016 11 10; View cancer-associated fibroblasts promotes invasion and proliferation. Res. 11; 29(6):656-668. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27482935) Combined nivolumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27622997) 2016 09 1(14):e89014. T-cell migration in metastatic renal cell 30; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27571927) VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. Radiographic Clinical Course. Clin Cancer Res. 2016 15; 22(24):6051-6060. View Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated Cancer immunotherapy trials: leading a shift in J Immunother Cancer. 2016; 4:42. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27437105) Relapse Transplantation. J Med. 2016 Jul in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27410923) with combined BRAF/MEK inhibition after discontinuation therapy: a clinical challenge. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27401151) Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer. 2016 07 12; 115(2):252-60. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27380136) Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck patients. J Immunother Cancer. 2016; 4:32. and 1(9):e87415. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27699275) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016 09; 90(3):638-47. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27282937) Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, 17(7):943-955. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27269740) Landscape of tumor-infiltrating T cell repertoire of human Nat Genet. 2016 07; 48(7):725-32. adaptations: Perspectives from the RECIST Working Group. 07; 62:138-45. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27237360) RECIST 1.1-Update and View in: Tumour CD274 66(8):1463-1473. View Res. 2016 07 01; 22(13):3127-31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27146699) Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Apr 19; 315(15):1600-9. View in: for PD-L1 Expression Cell the Apr; 2(4):518-22. View Ligands (PD-L1 and PD-L2) in Histiocytic and Criteria and RECIST v1.1 in Patients With Advanced to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 4(4):289-93. Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016 01; 76(5):999-1008. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26833127) Melanoma in 2015: Clin 2016 Feb; 13(2):77-8. Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. Therapy in Renal Cell Carcinoma. Cancer Immunol Res. Nov 21(22):4989-91. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26567357) PD-L1 Antibodies to Its Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Dec; 3(12):1308-15. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26546452) Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 09 24; 373(13):1270-1. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26398076) Inhibition of Immune Checkpoints and Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Front Oncol. 2015; 5:202. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26442214) Invest. 2015 Sep; 125(9):3377-83. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26325034) Phase 2 patients with mucosal or in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26264378) Corticosteroids and immune checkpoint 7(8):521-2. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26298620) Anti-PD-1-Related Pneumonitis 16(8):908-18. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26115796) Radiographic Profiling of Adverse in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Oct; 3(10):1185-92. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26100356) Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28147717) sequencing reveals high Med. 2015 Jul 02; 373(1):23-34. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26027431) A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic Nov; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26451318) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015 Jun; 16(6):e270-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26065612) Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunol Res. 2015 Aug; 3(8):855-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26014096) Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res. 2015 Oct; 3(10):1158-64. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26014095) A Phase I Trial of Sorafenib Malignant Melanoma. Oncologist. 2015 Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. Med. 2015 May 21; 372(21):2006-17. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25891304) Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol. 2015 15; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25805798) immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. Eur J Radiol. 2015 Jul; 84(7):1259-68. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25937524) Genetic cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment 28(3):357-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25515650) Nivolumab versus chemotherapy in patients advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, open-label, 2015 Apr; 16(4):375-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25795410) Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015 May 15; 21(10):2289-96. death ligand-1 Cancer. 2015; 3:3. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25767716) Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015 Apr; not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2015 Feb 15; 21(4):749-55. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25538262) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27; 515(7528):563-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25428504) Response with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer. 2014; 2(1):40. View in: to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30. View in: Immunity to the vacuolar ATPase complex accessory unit ATP6S1 in patients with malignant Immunol a JAMA. 2014 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25369488) Future \"Melanoma Bridge\", Napoli, View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25348889) melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20; 384(9948):1109-17. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25034862) Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 2014 Oct; 40(9):1056-64. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25060490) Immune checkpoint blockade for glioblastoma: activity of single agent and combinatorial View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25165207) The role of whole brain radiation therapy in the management of melanoma brain metastases. Radiat Oncol. 2014 Jun 22; safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma Clin 2014 Jun tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014; inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54. View granuloma formation by CD4+ T cells in patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity Oncol. 2015 Feb 20; 33(6):e32-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24616309) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014 Apr patients with metastatic melanoma treated with immunotherapy prior to or after BRAF 120(11):1695-701. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24577748) Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol View single-arm, of vemurafenib in patients with metastatic melanoma in the United States. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24445759) Metastatic mucosal melanoma: imaging Imaging. 2013 Dec 30; 13(4):626-32. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24434078) Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood. 2014 Feb following ipilimumab associated with severe hypothyroidism and Immunol clinical benefit in melanoma patients. Clin Cancer Res. 2013 Oct 01; 19(19):5300-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24089443) Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e396-406. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23993384) Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e407-16. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23993385) The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013 Oct 15; 119(20):3687-95. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23913718) Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23775962) Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013 Jul; 18(6):733-43. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23774827) Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013 Jul 15; 19(14):3936-43. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23743568) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl melanoma. Oncologist. 2013 Jun; 18(6):717-25. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23709751) Treatment for melanoma: new drugs, new opportunities, new challenges. Oncology May; View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23550685) Melanoma, version B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention. Chin Clin Oncol. 2013 Mar; 2(1):7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25841448) Efficacy retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res. 2013 Apr 15; 19(8):2232-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23444228) Activity of the heat melanoma. PLoS One. 2013; 8(2):e56134. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013 May 01; 119(9):1675-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23400564) BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 01; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23307859) The activation of cells resistant to BRAF inhibition promotes PD-L1 that is reversible by MEK PI3K inhibition. Cancer 2012 Dec 15; 18(24):6580-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23087408) When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst. 2012 Oct 17; 104(20):1534-41. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22927506) Future perspectives in melanoma research. Meeting report from the \"Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011\". J MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. J Clin Oncol. 2012 Jun 20; 30(18_suppl):CRA2509. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28140805) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 366(26):2443-54. genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2012 Apr 05; 12(5):349-61. View in: c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic Res. 2012 Apr; 22(2):123-32. View with melanoma brain metastases: open-label, phase 2 critical hurdles in cancer immunotherapy. J Med. 2011 Vemurafenib of metastatic melanoma. Cancer Res. 2012 Jan immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR Am J Roentgenol. 2011 Aug; 197(2):W241-6. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21785048) A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2011 May Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous Oncol. 2011 May 20; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28021164) Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. Oncol. in: antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21467163) Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 2010 Dec 15; 70(24):10150-60. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21159637) endpoints for 2010 Sep 22; 102(18):1388-97. with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol. 2010 20; 28(18_suppl):4. View ipilimumab in patients with metastatic melanoma. N Engl Aug T-cell activation by melanoma initiating Res. 2010 Jan 15; 70(2):697-708. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20068175) Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. Pigment Cell Melanoma Res. 2010 Feb; 23(1):14-26. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20025711) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. Dec 01; View in: gene mutations and copy melanoma Cancer Res. 2008 [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18980976) Adoptive transfer of antigen-specific CD4+ [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18545145) CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res. 2008 Jun 15; 14(12):3896-905. View of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol. 2008 May 20; 26(15_suppl):3007. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27947618) Prolonged in objective responders ipilimumab therapy. Clin Oncol. 2008 May 20; 26(15_suppl):20004. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27947906) Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an monoclonal [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27947617) II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008 May activity of factor-secreting vaccines. Immunol Rev. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18364009) Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res. 2008 Apr; 7(4):1490-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18311903) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008 Feb 26; 105(8):3005-10. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18287062) Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. generated using an artificial antigen-presenting cell. Clin Cancer Res. 2007 Mar 15; 13(6):1857-67. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17363542) High-throughput oncogene mutation profiling Nat Genet. 2007 Mar; 39(3):347-51. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17293865) Case records of the Massachusetts General Hospital. Case 2-2007. A 49-year-old woman with a pigmented lesion on the arm. N Engl J Med. 2007 18; 356(3):285-92. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17229956) Therapy-induced antibodies to MHC class I chain-related protein immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16754847) Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage. Clin Cancer Res. 2006 Feb 01; antibody vaccinated melanoma and ovarian cancer patients. Keystone Symposia: Advances in the understanding and treatment Immunotherapy - a thematic volume of Advances in Immunology. Elsevier Academic Press. 2006; 90:341-368. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16278389) Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report. Cancer Immun. 2005 May 19; 5:7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15901138) Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. antigen-4 blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF). J antigen-4 blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF). Proceedings of ASCO. 2004. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments of cytotoxic T antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci A. 2003 Apr 15; 100(8):4712-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12682289) MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun. 2003 immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2003 Mar 18; 100(6):3398-403. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12626761) Vaccination with irradiated autologous engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with lung Clin Oncol. 2003 View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12586798) Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor augments anti-tumor immunity in patients with metastatic non-small cell lung carcinoma. Journal of Clinical Oncology. 2003; 21:624-630. The inhibitor of apoptosis protein ML-IAP is a target for immune mediated tumor destruction. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100:3398-3403. Vaccination with Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony Stimulating Factor by Adenoviral Mediated Gene Transfer Augments Anti-tumor Immunity in Patients with Metastatic Melanoma. 2003; 21:3343-3350. antigens in study destruction. Proc Natl Acad Sci U S A. 2002 May 14; 99(10):6919-24. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11983866) Skin cancer. in Atlas Oncology. 2002; Interleukins and Cancer. in Encyclopedia of 523-535. Identification of novel antigens in chronic lymphocytic leukemia by SEREX: Assessment of their potential as targets for immunotherapeutic approaches. Blood. 2002; 100:2123-2131. A phase I/II A/MART-1-encoding melanoma. Proceedings of ASH. 2001. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J. May-Jun; 6(3):139-45. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10882328) Adjuvant high-dose interferon Alpha-2b in high-risk melanoma. Cancer J Sci Am. 2000; 6:139-45.. Immunologic Gene Therapy of Melanoma: Phase I Study of Therapy with Autologous Dendritic Cells Transduced with Recombinant Adenoviruses Encoding Melanoma Antigens. Proceedings of ASCO. 2000. Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma. Proceedings of ASCO. 1999. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad 27; 95(22):13141-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9789055) Genetically modified tumor Am. 1998 Oncology Clinics of North America. 1998; 7:471-485. The molecular genetics of familial malignant melanoma. Journal of Clinical Oncology. 1998; 16:670-682. Gender as a factory influencing the toxicity of adjuvant chemotherapy for colorectal cancer. Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, K\u00f6ln, Germany. 1995. Age as a factor influencing the toxicity of adjuvant chemotherapy for colorectal cancer. Genoa, Italy. Second International Conference on Geriatric Oncology. 1994. High-dose therapy and growth factor mobilized peripheral blood progenitor cell support for responding patients with metastatic breast Clin Biol Res. 1994; 389:487-95. JAMA. 1991 Dec 18; 266(23):3285. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1960825) Genetically distinct cell populations in naturally occurring bone marrow-chimeric primates express similar MHC class I gene products. J Immunol. 1990 May 15; 144(10):3726-35. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2110210) Use of cDNA probes specific for the human MHC class II beta loci for tissue-typing nonhuman primates at their class II beta loci. Transplantation. 1989 Jul; 48(1):170-3. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2568708) A primate species with histocompatibility complex class I polymorphism. Proc Natl Acad A. 1988 Oct; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2902637) Prevalence of antibodies to 3 retroviruses in a captive colony of macaque monkeys. Int J Cancer. 1988 Apr 15; 41(4):601-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2895751) Prevalance of antibodies to three retroviruses in a captive colony of Macaque monkeys. International "}